BSI-001 / Biosion, Anhui Anke Biotech - LARVOL DELTA

BSI-001, a novel anti-HER2 antibody exhibiting potent synergistic efficacy with trastuzumab (AACR 2022) - "BSI-001 is the best functional partner of trastuzumab identified through the SynAbTM platform. BSI-001 binds to a unique epitope, distinct from the binding epitopes of trastuzumab and pertuzumab. It exhibits superior bioactivity and efficacy in vitro and in vivo when combined with trastuzumab."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor